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Abstract
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited genetic disease 
characterized by compensatory pathological left ventricle (LV) hypertrophy due to sarcomere 
dysfunction. In an important proportion of patients with HCM, the site and extent of cardiac 
hypertrophy results in severe obstruction to LV outflow tract (LVOT), contributing to disabling 
symptoms and increasing the risk of sudden cardiac death (SCD). In patients with progressive 
and/or refractory symptoms despite optimal pharmacological treatment, invasive therapies that 
diminish or abolish LVOT obstruction relieve heart failure-related symptoms, improve quality 
of life and could be associated with long-term survival similar to that observed in the general 
population. The gold standard in this respect is surgical septal myectomy, which might be 
supplementary associated with a reduction in SCD. Percutaneous techniques, particularly 
alcohol septal ablation (ASA) and more recently radiofrequency (RF) septal ablation, can 
achieve LVOT gradient reduction and symptomatic benefit in a large proportion of HOCM 
patients at the cost of a supposedly limited septal myocardial necrosis and a 10-20% risk of 
chronic atrioventricular block. After an initial period of enthusiasm, standard DDD pacing failed 
to show in randomized trials significant LVOT gradient reductions and objective improvement 
in exercise capacity. However, case reports and recent small pilot studies suggested that atrial 
synchronous LV or biventricular (biV) pacing significantly reduce LVOT obstruction and 
improve symptoms (acutely as well as long-term) in a large proportion of severely symptomatic 
HOCM patients not suitable to other gradient reduction therapies. Moreover, biV/LV pacing in 
HOCM seems to be associated with significant LV reverse remodelling. 
Keywords:   hypertrophic obstructive cardiomyopathy, intraventricular gradient, biventricular 
pacing,   reverse   remodelling.                                                                                
Introduction
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited genetic disease 
characterized   by   compensatory   LV   hypertrophy   mainly   due   to   sarcomere   dysfunction. 
Prevalence of the disorder in the general population is estimated to be 0.2% [1]. A subset of 
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patients with HCM has hypertrophic obstructive cardiomyopathy (HOCM), in which systolic 
septal bulging into the LVOT, malposition of the anterior papillary muscle, with enlarged 
posterior mitral leaflet and hyperdynamic LV contraction and drag forces, through a Venturi 
effect, provoke systolic anterior motion of the anterior leaflet of the mitral valve (SAM), 
contributing to the creation of the LVOT gradient. The degree of LVOT obstruction is generally 
variable, with only a minority of patients presenting significant LVOT gradient at rest. In the 
majority of HOCM the LVOT obstruction is only "latent" or "provocable" by stimuli such as 
exercise, drugs (amyle nitrate), Valsalva maneuver and postextra- systolic potentiation [2]. 
Resting   (basal)   obstruction   in   HOCM   is   an   independent   predictor   of   adverse   clinical 
consequences such as progressive heart failure and cardiovascular death, including sudden 
cardiac   death   (SCD)   [3,4].                                                                  
Overview   of the  treatment  in  HOCM                                                                
Medical therapy is at least partially effective in the majority of HOCM patients [5] and consists 
of beta-blockers, calcium channel blockers and disopyramide, the later being of particular 
benefit in patients with associated atrial fibrillation due to its atrial antiarrhythmic properties.
In severely symptomatic HOCM patients despite optimal medical treatment and with significant 
resting or provocable LVOT obstruction (with gradient ≥30 mm Hg at rest or ≥50 mm Hg during 
exercise) non-pharmacologic treatment is indicated [5]. Invasive therapies should be able to 
alleviate   LVOT   obstruction   either   by   increasing   LVOT   systolic   diameter   and/or   by 
reducing/eliminating SAM. Surgical septal myectomy is the gold standard in this respect, being 
able to concomitantly eliminate anomalies of mitral valve apparatus by concomitant mitral valve 
repair.
Surgical myectomy is effective in >90% of patients, with long-term survival similar to that of 
the general population [6] and a potential association with a reduction in SCD [7]. In 
experienced centres perioperative mortality is <1% and risk of atrioventricular bock (AVB) is 
<3% [8]. The rate of perioperative mortality and major complications may be significantly 
higher in patients with significant co-morbidities, particularly in those over 65 years old [9,10].
Percutaneous alcohol septal ablation (ASA) can achieve significant LVOT gradient reduction 
and symptomatic benefit in approximately 80% of HOCM patients, with long-term survival 
comparable with surgical myectomy. ASA-related mortality is 1.5-3% and there is a 10-20% 
risk of chronic AVB [11-13]. Moreover, 9 to 13% of patients require a second procedure and 3-
5%   surgical   myectomy   [11,12].   There   is   also   ongoing   concern   about   SCD/ventricular 
arrhythmia due to ASA-induced septal myocardial necrosis, which might in the long term 
behave as an arrhythmogenic substrate. Although to date most of the reports suggest that ASA is 
not associated with an increase in SCD/ventricular arrhythmia [14], it is worrisome that 
successful LVOT gradient reduction by ASA does not reduce the risk for malignant arrhythmias 
in   high-risk   HOCM   patients   [15,16].                                                            
Percutaneous radiofrequency (RF) septal ablation is a recently introduced method that can 
relieve LVOT gradient through RF-induced necrosis in the basal septum. It has the theoretical 
advantages that it is not dependent on coronary artery anatomy and can precisely identify His 
bundle and its branches and therefore avoid their damage. However, recently published small 
series showed persistent significant LVOT gradient in more than 20% of the HOCM patients, 
with significant perioperative mortality and life-threatening complications (including malignant 
ventricular arrhythmia), and a >20% rate of AVB [17,18]. Moreover, for the moment data on 
long-term risk for SCD/ventricular arrhythmia are lacking.                                                       
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DDD   pacing   in   HOCM                                                                        
Surgical myectomy and ASA can carry unacceptable risks and/or are not suitable in selected 
subsets of patients with HOCM and severe LV obstruction. Dual-chamber (DDD) pacing with a 
short atrioventricular delay, a widely available alternative, initially raised interest for the 
treatment of LVOT obstruction. Two main mechanisms, systolic and diastolic, are known to be 
involved in reducing LV gradient with DDD-right ventricular apex (RVA) pacing. The systolic 
mechanism relies on the paradoxical motion of the interventricular septum induced by altered 
LV depolarization, which delays contraction of the basal interventricular septum and therefore 
increases the systolic dimension of the LVOT [19] with secondary reduction in systolic anterior 
motion of the mitral valve. The diastolic mechanism relies on the improved LV filling due to 
optimized timing of atrial systole [20]. Observational studies and a non-blinded randomized trial 
have suggested that DDD pacing produces gradient reduction, with symptomatic and functional 
benefit [21-23]. Subsequent single and multicentre randomized trials demonstrated average 
LVOT gradient reductions of only 50 percent and no improvement in exercise capacity [24-26], 
suggesting a placebo effect for the symptomatic improvement [24,27]. One possible explanation 
for this limited response could be that the change in motion of the interventricular septum 
induced by RVA pacing is too small to significantly reduce the LVOT gradient, because many 
HOCM patients have a very rapid AV conduction [28] and/or the RVA sites are at a distance 
away from the LV apex [29]. Moreover, recent long-term follow-up data suggests that DDD 
pacing in HOCM patients might have a deleterious effect on survival and heart failure by 
comparison with conservative management [30]. Based on some of these data current guidelines 
assign a class IIb indication for DDD pacing in HOCM patients without a bradycardia indication 
[5,31].
The case of atrial synchronous LV or biventricular pacing in HOCM                                
A small number of case reports showed that atrial synchronous LV or biventricular pacing (biV) 
might further reduce the LV pressure gradient and improve symptoms in HOCM, initially in 
patients with intraventricular conduction delay [32]. Later on, LV/biV pacing showed a 
significant LVOT gradient reduction superior to RVA pacing in HOCM patients without 
intraventricular conduction delay [29,33-35]. Recently, published data from three small studies 
suggest that LV/biV pacing might be efficient for LVOT gradient reduction and symptom 
improvement in a large proportion of HOCM patients not suitable for myectomy or ASA (Table 
1) [36-39].
Table 1
Mechanisms of LVOT gradient reduction with LV/biV pacing                              
In contrast to RVA pacing, LV/biV pacing might be able to induce a supplementary reduction in 
LVOT gradient by an alteration in the contraction of a larger area of the LV. Alternatively, the 
reversed   LV   depolarization   sequence   [35]   caused   by   pre-excitation   of   the   LV 
posterolateral/lateral wall during LV/biV pacing may activate the longitudinally oriented 
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epicardial fibres earlier, thereby advancing lateral wall longitudinal displacement with regard to 
interventricular septal longitudinal displacement [36] and potentially even slightly stretching the 
latter. This will change the pre-ejection shape and diameter of the LVOT and mitral valve, 
which, together with the induced reduction in septal systolic displacement, can reduce the 
intraventricular gradient. Support for the latter hypothesis comes from a case report showing that 
DDD RVA epicardial pacing for complete AV block after septal myectomy induced SAM and 
LVOT gradient, while LV lateral wall pacing completely abolished it [39]. SAM disappearance 
was also observed in the majority of HOCM patients after 6 months of LV/biV pacing [37].
LV/biV   implant   procedure   outcome                                                            
Recently published small studies with LV/biV pacing in HOCM showed an acute success rate of 
transvenous LV lead implantation ranging from 75-80% [36,37] to 100% [39] compared to the 
94.4% CRT implantation rate in patients with LV systolic dysfunction [40] or 100% in patients 
with dilated (end-stage) phase of hypertrophic cardiomyopathy [41]. Causes of LV lead 
implantation failure were: impossibility to cannulate coronary sinus (CS) ostium [36,37], intense 
phrenic nerve stimulation despite LV repositioning [37] and CS dissection [37]. Possible 
explanations are the smaller and/or tortuous coronary sinus and its ventricular branches in 
concentrically hypertrophied non-dilated LV of HOCM patients (Figure 1), as well as the 
limited experience of the operators in this population and/or lack of specifically adapted LV 
leads. It is possible that newer generation LV leads, with smaller diameter (around 4F for bipolar 
leads) and better trackability could help to increase success rates. A low rate of LV lead or 
device-related complications have been described on long–term follow-up, although in one of 
the three small pilot studies the LV lead was extracted in three of eight cases (one due to device 
infection) [37]. Additionally, in a very recent retrospective analysis of a single-centre ICD 
registry  in  patients   with  HCM,  22% of  the  CRT-D  subgroup showed LV   lead-related 
complications [42].
Figure 1: A: RAO projection showing the occlusive venography in a hypertrophic obstructive cardiomyopathy 
patient; note the extreme tortuousity as well as the reduced diameter of the target coronary sinus ventricular branch. 
B: The same RAO projection showing the final lead position of the leads (a 4F bipolar lead was used).
Symptoms and functional capacity                                                                           
Small long-term pilot studies have shown improvements of at least one NYHA functional class 
with LV/biV pacing [36] even in less symptomatic HOCM patients [37], with a marked and 
progressive increase in quality of life [36,38] and functional capacity evaluated by 6-minute 
walk test (6MWT) [36,37], treadmill exercise test [38] or peak oxygen consumption (VO2 peak) 
[37] (Table 1). In one of the studies a non-uniform response to LV/biV pacing was observed: 
two out of eight patients were symptomatic non-responders, three responded to biV pacing and 
three to RVA pacing [38]. However, in this study the optimal pacing configuration was 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 12 (3): 114-123 (2012)Vatasescu R et al, “Biventricular / Left Ventricular Pacing in HCM”                                  118
established by the maximum symptomatic benefit observed after a serial crossover comparison 
between no active pacing vs. RVA pacing or biV pacing. Additionally, in non-responders mean 
LVOT gradient at rest was less significant (around 25 mm Hg) and in three out of eight patients 
previous septal reduction therapies failed (ASA in two patients and myectomy in another one) 
[38]. Other studies decided the optimal pacing configuration to be the one that acutely induces 
the maximum LVOT gradient reduction [36,37], possibly explaining their higher rate of 
responders. Overall LV/biV seems to favourably compare with studies on DDD RVA pacing in 
HOCM,   which   failed   to   show   significant   improvement   in   functional   capacity   [24-26].
LVOT   obstruction                                                                                          
In the overwhelming majority of HOCM patients LV/biV pacing is acutely more effective for 
gradient reduction than standard RVA pacing: eight out of nine in one study [36] and all nine 
patients in another [37]. Even when optimal pacing configuration was selected by symptomatic 
improvement, clinical non-responders and patients selected for RVA pacing still achieved a 
greater reduction in LVOT gradient with biV pacing. [38] (Table 1). Moreover, LVOT gradient 
progressively decreased during follow-up, with a mean LVOT gradient at rest below 30 mm Hg 
at medium term [36,37], reaching almost non-significant levels at three years [37]. Acutely, 
SAM   is   still   present   (although   with   a   significantly   reduced   contact   time;   unpublished 
observations, Dr. Vidal) [36]. Long-term, LV/biV pacing is associated with a continuous 
reduction of SAM [36] or even complete disappearance in the majority of HOCM patients [37] 
(Figure 2). This is concordant with a continuous and significant reduction in the degree of 
mitral   regurgitation   [36].   Interestingly,   one   of   the   studies   showed   that   the   optimal 
atrioventricular and interventricular intervals for maximum LVOT gradient reduction at six 
months follow-up were different than those at baseline for more than 50% of the patients [37].
Figure 2: Upper panels show Mmode scans across the left ventricle and the mitral valve before (preBiv) and after 
atrial synchronous biventricular pacing (postBiv): arrows indicate systolic anterior motion (SAM) of the mitral 
valve, which touches the septum preBiv and does not contact it postBiv. These changes in the degree of SAM are 
concomitantly seen with a significant decrease of LVOT gradient (from 76 to 48 mmHg). In this patient, atrial 
synchronous right ventricular apical pacing did not change the left ventricular outflow tract gradient.
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LV   reverse   remodeling                                                                                    
In contrast to studies with DDD RVA pacing, LV/biV pacing showed that the reduction in LVOT 
gradient induced a progressive and significant reduction in LV mass (reverse remodelling) [36]. 
The thinning seems to be significant only for the interventricular septum [36,37], although there 
was also a trend in the LV posterior wall [36]. This is not surprising, considering that LV 
hypertrophy in young patients with HOCM is at least partially also secondary to LVOT 
obstruction [43] and that septal reduction therapies induce LV reverse remodelling, with wall 
thinning in areas distant from the interventricular septum [44,45].                               
LV/biV pacing in HOCM and SCD / ventricular arrhythmia                                    
During long term LV/biV pacing in HOCM there was no SCD/syncope in patients with CRT-P 
[36-38]. In the group of CRT-D patients, only one experienced appropriate ICD therapies [37]. 
Although the pooled number of studies with LV/biV pacing in HOCM is small, it is tempting to 
speculate that this therapy, which is able to reduce LVOT gradient and induce LV reverse 
remodelling without creating a septal scar, does not increase the SCD/VA risk. Data from CRT 
studies in patients with LV systolic dysfunction also demonstrate that the risk of SCD/VA is 
reduced in the presence of significant LV reverse remodeling [46, 47].                                
Limitations  
The small number of patients included in studies with LV/biV pacing in HOCM as well as the fact 
that all of them are observational and uncontrolled (i.e., a placebo effect of pacing cannot be 
excluded) requires caution in interpreting the results. However, the differences observed in 
comparison with standard DDD RVA pacing warrants further research. Considering the relatively 
large number of HOCM patients submitted to cardioverter-defibrillator implantation for primary 
or   secondary   prevention,   data   for   such   analysis   should   be   readily   available.  
Conclusion  
In selected patients with HOCM, LV/biV pacing is feasible and usually the best configuration for 
gradient   reduction.   Overall,   LV/biV   pacing   in   patients   with   HOCM   significantly   and 
progressively improves functional capacity and quality of life. It may also induce LV reverse 
remodelling.
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